Live price temporarily unavailable.
Kailera Therapeutics (KLRA) is a Health Care company in the Russell 2000. Latest news and coverage below.
| Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|
| Income statement | ||||
| Operating income | −$20.5M | −$30.7M | −$84.7M | −$121.4M |
| Net income | −$18.0M | −$28.9M | −$78.9M | −$111.3M |
| EPS (diluted) | −$17983.00 | −$28947.00 | −$3650.00 | −$1.09 |
| Balance sheet | ||||
| Cash and equivalents | $101.8M | $101.4M | $111.8M | $130.3M |
| Total assets | — | — | $624.8M | $1.21B |
| Total liabilities | — | — | $64.5M | $93.0M |
| Shareholders' equity | −$235.2M | −$262.6M | −$432.1M | $1.12B |
| Cash flow | ||||
| Operating cash flow | −$18.2M | −$26.2M | −$68.3M | −$77.5M |
From Kailera Therapeutics's 10-Q filings with the SEC. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
No recent news mentioning Kailera Therapeutics in our feed yet.